TNNT2 and androgen insensitivity syndrome: In the present study, we found that in AIS patients who underwent intravenous thrombolysis, (a) elevation of serum hs‐cTnT was associated with 90‐day mortality after treatment, (b) elevation of hs‐cTnT was not associated with END or any type of HT, (c) older age and TOAST etiology (more cardioembolic etiology) were associated with hs‐cTnT elevation, and (d) hs‐cTnT ≥15.4 ng/L predicts mortality with acceptable sensitivities and specificities.